Pharmaceutical

FDA denies approval for Astellas’ investigational gastric cancer drug

Approval for zolbetuximab was quashed after the FDA found deficiencies in the company’s third-party manufacturing.

Jan 9, 2024 - 18:00
FDA denies approval for Astellas’ investigational gastric cancer drug
Approval for zolbetuximab was quashed after the FDA found deficiencies in the company’s third-party manufacturing.
Read the original article

Tags:

Previous Article

No pain data yet from Vertex, and sky high deal expectations at JPM 2024

Next Article

Zealand raises DKr1.45bn to advance obesity pipeline

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

For pharma companies, the possibilities of green chemistry are huge

For pharma companies, the possibilities of green chemis...

Nov 1, 2024

After loved ones’ long-awaited organ transplants, caregivers often find challenges are just beginning

After loved ones’ long-awaited organ transplants, careg...

Jan 4, 2024

Group behind ProMED fires three top moderators amid strike

Group behind ProMED fires three top moderators amid strike

Sep 8, 2023